Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Clin Lung Cancer. 2009 Jul;10(4):244-8. doi: 10.3816/CLC.2009.n.033.
Malignant pleural mesothelioma (MPM) is a primary malignancy characterized by local invasion of the pleura and metastasis. Despite advances in computed tomography (CT) and magnetic resonance imaging (MRI), accurately staging patients remains challenging. Recent studies have examined the use of integrated CT-positron emission tomography (PET) for staging patients.
Mayo Clinic databases were queried to identify cases with a histologic diagnosis of MPM from 2000 to 2006. Inclusion criteria were a diagnosis of MPM, an available CT scan, and an initial staging integrated CT-PET scan. A total of 35 patients were identified who met the inclusion criteria. Computed tomography and integrated CT-PET scans were reviewed by experienced radiologists. Laboratory parameters were reviewed. The Mayo Clinic tumor registry and Social Security database were queried for survival data in patients in which no follow-up was available.
Findings on integrated CT-PET excluded 14 of 35 patients from surgical intervention. Extrapleural pneumonectomies (EPPs) were performed in 8 patients, and partial pleurectomies were performed in 2 patients. Upstaging from integrated CT-PET occurred in 70% of the patients when surgical pathology was available, 2 cases to an inoperable stage. Although not statistically significant, median survival was 20 months for patients undergoing an EPP and 12 months for patients excluded from surgical intervention by integrated CT-PET.
Malignant pleural mesothelioma is a difficult disease to accurately stage. The most common reason for upstaging in our series was an increase in T (tumor; tumor-node-metastasis staging system) disease. Our data suggest that integrated CT-PET is excellent for detecting nodal and distant metastases. However, the ability of this imaging modality to correctly stage locoregional disease is not superior to the combination of CT and MRI as reported in the literature.
恶性胸膜间皮瘤(MPM)是一种以胸膜局部浸润和转移为特征的原发性恶性肿瘤。尽管计算机断层扫描(CT)和磁共振成像(MRI)技术有所进步,但准确分期患者仍然具有挑战性。最近的研究已经检查了使用整合 CT-正电子发射断层扫描(PET)对患者进行分期的情况。
从 2000 年到 2006 年,梅奥诊所的数据库被查询以确定组织学诊断为 MPM 的病例。纳入标准为 MPM 诊断、可获得 CT 扫描和初始分期整合 CT-PET 扫描。共确定了 35 名符合纳入标准的患者。经验丰富的放射科医生对 CT 和整合 CT-PET 扫描进行了审查。审查了实验室参数。在无法进行随访的患者中,通过梅奥诊所肿瘤登记处和社会安全数据库查询了生存数据。
整合 CT-PET 的结果排除了 35 名患者中的 14 名进行手术干预。对 8 名患者进行了胸膜外全肺切除术(EPP),对 2 名患者进行了部分胸膜切除术。当获得手术病理时,70%的患者在整合 CT-PET 时被升级分期,其中 2 例为不可手术阶段。尽管没有统计学意义,但接受 EPP 的患者的中位生存期为 20 个月,而被整合 CT-PET 排除手术干预的患者的中位生存期为 12 个月。
恶性胸膜间皮瘤是一种难以准确分期的疾病。在我们的系列中,升级分期最常见的原因是 T(肿瘤;肿瘤-淋巴结-转移分期系统)疾病的增加。我们的数据表明,整合 CT-PET 非常适合检测淋巴结和远处转移。然而,与文献中报道的 CT 和 MRI 相结合相比,这种成像方式正确分期局部疾病的能力并不优越。